Pronunciation: (hī"bri-dō'mu),[key] —n., —pl.-mas.Biotech. a hybrid cell made in the laboratory by fusing a normal cell with a cancer cell, usu. a myeloma or lymphoma, in order to combine desired features of each, as the ability of the cancer cell to multiply rapidly with the ability of the normal cell to dictate the production of a specific antibody. Cf. monoclonal antibody.